Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer. - Fu R; Wang Y; Rehman I; Bedford E; Sharif S; Nguyen ND; Powell RT; Adams A; Liu W; Wang S; He W; Lu Y; et al. (BioRxiv : the preprint server for biology, 2026)